MichelleA.FanaleMD

Oncology • Bothell, WA

Hematologic Oncology

Executive Medical Director, Lymphoma Strategy

Join to view full profile

Dr. Fanale is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Fanale's full profile

Already have an account?

Office
Seagen - Headquarters
21717 30th Drive S.E, Building 3
Bothell, WA 98021
Phone+1 425-527-4000
Is this information wrong?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Rutgers New Jersey Medical SchoolClass of 1999
Rutgers College BA, Biochemistry/ Molecular Biology & Psychology , 1990 - 1994

Certifications & Licensure

TX State Medical License 2002 - 2022
AZ State Medical License 2001 - 2017
MN State Medical License 2000 - 2015

Clinical Trials

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma Start of enrollment: 2006 Aug 01
Terminated
Phase 2
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma Start of enrollment: 2007 Feb 01
Completed
Phase 1
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma Start of enrollment: 2008 Mar 19
Completed
Phase 2
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. Start of enrollment: 2009 Aug 24
Completed
Phase 2
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma Start of enrollment: 2011 Jun 21
Completed
Phase 1
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma Start of enrollment: 2011 Nov 01
Active, not recruiting
Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
A Safety Study of SGN-CD19A for B-Cell Lymphoma Start of enrollment: 2013 Feb 01
Completed
Phase 1
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Start of enrollment: 2013 Jul 17
Completed
Phase 1
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) Start of enrollment: 2014 Aug 12
Completed
Phase 2
Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma Start of enrollment: 2016 May 13
Active, not recruiting
Phase 2
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma Start of enrollment: 2017 Mar 08
Recruiting
Phase 1, Phase 2
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL Start of enrollment: 2017 Apr 24
Active, not recruiting
Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Start of enrollment: 2017 May 25
Active, not recruiting
Phase 2
Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Start of enrollment: 2017 Jul 18
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

14 citations
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Jason Westin, R Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, ...> ;Journal of Clinical Oncology. 2023 Feb 1
1 citations
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
Mridula Krishnan, R. Gregory Bociek, Michelle A. Fanale, Swaminathan P. Iyer, Mary Jo Lechowicz, Philip J. Bierman, James O. Armitage, Matthew A. Lunning, Avyakta Kall...> ;Annals of Hematology. 2021 Oct 20
63 citations
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 tr...
David J. Straus, Monika Długosz-Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech-Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. S...> ;The Lancet. Haematology. 2021 Jun 1
1 citations
Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follic...
Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle A. Fanale, Loretta J. Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. ...> ;Leukemia & Lymphoma. 2021 Jan 2
14 citations
Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne Velez-Bravo, Tamara G. Barnes, Fredrick B. Ha...> ;Clinical Cancer Research. 2020 Nov 1
64 citations
Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma
Mark Roschewski, Kieron Dunleavy, Jeremy S. Abramson, Bayard L. Powell, Brian K. Link, Prapti A. Patel, Philip J. Bierman, Deepa Jagadeesh, Ronald T. Mitsuyasu, David ...> ;Journal of Clinical Oncology. 2020 May 26
6 citations
Cost-effectiveness of brentuximab vedotin with chemotherapy in treatment of CD30-expressing PTCL.
Tatyana Feldman, Denise Zou, Mayvis Rebeira, Joseph K. T. Lee, Michelle A. Fanale, Thomas Manley, Shangbang Rao, Joseph Feliciano, Mack Harris, Anuraag Kansal> ;The American Journal of Managed Care. 2020 Feb 1
5 citations
De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era.
Bei Hu, Loretta J. Nastoupil, Sanam Loghavi, Jason R. Westin, Beenu Thakral, Luis Fayad, Fredrick B. Hagemeister, Sattva S. Neelapu, Felipe Samaniego, Hun J. Lee, Mich...> ;Leukemia & Lymphoma. 2020 Jan 28
17 citations
A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas
Paolo Strati, Loretta J. Nastoupil, Richard E. Davis, Luis Fayad, Nathan Fowler, Fredrick B. Hagemeister, Larry W. Kwak, Yasuhiro Oki, Michael Wang, Jason R. Westin, C...> ;Haematologica. 2020 Jan 1
34 citations
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
Melody R. Becnel, Loretta J. Nastoupil, Felipe Samaniego, Richard E. Davis, M. J. You, Michael R. Green, Fredrick B. Hagemeister, Michelle A. Fanale, Luis Fayad, Jason...> ;British Journal of Haematology. 2019 Jun 1
5 citations
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
Tamer Khashab, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro, Peter McLaughlin, M. Alma Rodriguez, Sattva S. Neelapu, Luis Fayad, Anas Y...> ;British Journal of Haematology. 2019 May 1
4 citations
Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.
Oded Sagiv, Sudip D. Thakar, John T. Manning, Thomas J. Kandl, Luis Fayad, Nathan Fowler, Fredrick B. Hagemeister, Michelle A. Fanale, Chelsea C. Pinnix, Felipe Samani...> ;Ophthalmic Plastic and Reconstructive Surgery. 2019 May 1
6 citations
Erratum to: Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma: Low-dose radiotherapy for adnexal b-cell lymphoma (Head & Neck, (2...
Chelsea C. Pinnix, Bouthaina S. Dabaja, Sarah A. Milgrom, Grace L. Smith, Zeinab Abou Yehia, Loretta J. Nastoupil, Jorge E. Romaguera, Francesco Turturro, Nathan Fowle...> ;Head & Neck. 2019 May 1
13 citations
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
Bastian von Tresckow, Michelle A. Fanale, Kirit M. Ardeshna, Robert T. Chen, Julia Meissner, Franck Morschhauser, Craig H. Moskowitz, Pier Luigi Zinzani, Hilde Giezek,...> ;Leukemia & Lymphoma. 2019 Apr 23
8 citations
Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta J. Nastoupil, Sattva S. Neelapu, Luis Fayad, Nathan Fowler, Chan Yoon Cheah> ;British Journal of Haematology. 2019 Apr 1
47 citations
A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma.
Sarah A. Milgrom, Hesham Elhalawani, Joonsang Lee, Qianghu Wang, Abdallah S.R. Mohamed, Bouthaina S. Dabaja, Chelsea C. Pinnix, Jillian R. Gunther, Laurence E. Court, ...> ;Scientific Reports. 2019 Feb 4
23 citations
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
Winnie S. Liang, Jo Anne Vergilio, Bodour Salhia, Helen J. Huang, Yasuhiro Oki, Ignacio Garrido-Laguna, Haeseong Park, Jason R. Westin, Funda Meric-Bernstam, David Fab...> ;The Oncologist. 2019 Feb 1
5 citations
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Dai Chihara, Shannon Wong, Tatyana Feldman, Michelle A. Fanale, Larysa Sanchez, Joseph M. Connors, Kerry J. Savage, Yasuhiro Oki> ;Hematological Oncology. 2019 Feb 1
11 citations
ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.
Paolo Strati, Michelle A. Fanale, Yasuhiro Oki, Francesco Turturro, Luis Fayad, Nancy L. Bartlett, Douglas E. Gladstone, Yvette L. Kasamon, Carol S. Portlock, Wyndham ...> ;Haematologica. 2019 Feb 1
406 citations
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven M. Horwitz, Owen A. O'Connor, Barbara Pro, Timothy M Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschh...> ;Lancet. 2019 Jan 19
9 citations
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
Dai Chihara, Yasuhiro Oki, Michelle A. Fanale, Jason R. Westin, Loretta J. Nastoupil, Sattva S. Neelapu, Luis Fayad, Nathan Fowler, Chan Yoon Cheah> ;Annals of Hematology. 2019 Jan 8
7 citations
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Ther...
Alison Yoder, Jillian R. Gunther, Sarah A. Milgrom, Dragan Mirkovic, Loretta J. Nastoupil, Sattva S. Neelapu, Michelle A. Fanale, Nathan Fowler, Jason R. Westin, Hun J...> ;Clinical Lymphoma, Myeloma & Leukemia. 2019 Jan 1
Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee.
Sarah A. Milgrom, Chelsea C. Pinnix, Jillian R. Gunther, Michelle A. Fanale, Bouthaina S. Dabaja> ;British Journal of Haematology. 2019 Jan 1
119 citations
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC...
Kieron Dunleavy, Michelle A. Fanale, Jeremy S. Abramson, Ariela Noy, Paolo Caimi, Stefania Pittaluga, Samir Parekh, Ann S. LaCasce, John Hayslip, Deepa Jagadeesh, Suni...> ;The Lancet. Haematology. 2018 Dec 1
6 citations
Beyond Chemotherapy: Checkpoint Inhibition and Cell-Based Therapy in Non-Hodgkin Lymphoma.
Paolo Strati, Shabnum Patel, Loretta J. Nastoupil, Michelle A. Fanale, Catherine M. Bollard, Adam Yuh Lin, Leo I. Gordon> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2018 May 23
Join now to see all

Journal Articles

Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin Lymphoma
Peter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Rituximab with ABVD vs ABVD for Advanced Stage High-Risk Classical Hodgkin Lymphoma: A Randomized Phase II Study
Francesco Turturro, Luis E Fayad, Anas Younes, Michelle Fanale, Yasuhiro Oki, Hun Ju Lee, Nancy L Bartlett, Haematologica

Lectures

Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

My B-cell Lymphoma Treatment During PregnancyJune 21st, 2018
Novel Agents Show Impressive Activity in Hodgkin LymphomaOctober 27th, 2017
Longer Nivolumab Response Reported in Hodgkin Lymphoma PatientsAugust 10th, 2017

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member